Indomethacin

Indomethacin

SCHEMBL43583

COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1.[KH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 9/20 0.98
PTGS1 known ✓ P23219 4/20 0.98
AKR1C3 P42330 7/20 0.98
AKR1C2 P52895 6/20 0.98
HIF1A Q16665 3/20 0.98
ABCB1 P08183 2/20 0.98
LMNA P02545 2/20 0.98
CYP1A2 P05177 2/20 0.98
CYP2D6 P10635 2/20 0.98
CYP2C9 P11712 2/20 0.98
GLO1 Q04760 2/20 0.98
NPSR1 Q6W5P4 2/20 0.98
AKR1C4 P17516 2/20 0.98
AKR1C1 Q04828 2/20 0.98
KDM4E B2RXH2 1/20 0.98
MEN1 O00255 1/20 0.98
PTGES O14684 1/20 0.98
ABCC3 O15438 1/20 0.98
ABCC4 O15439 1/20 0.98
ABCB11 O95342 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indomethacin SCHEMBL8352438 1.00 PTGS2 (0.98) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL11441233 0.99 PTGS2 (0.96) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL29525957 0.99 PTGS2 (1.00) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL9300 0.99 PTGS2 (1.00) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL3518614 0.99 PTGS2 (1.00) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL29353712 0.99 PTGS2 (1.00) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL23391006 0.98 PTGS2 (0.98) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL1817813 0.98 PTGS2 (0.98) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL6356562 0.98 PTGS2 (0.98) PTGS2AKR1C3AKR1C2PTGS1HIF1A
Indomethacin SCHEMBL22472310 0.98 PTGS2 (0.98) PTGS2AKR1C3AKR1C2PTGS1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7267 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
US-20260041660-A1 Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms CHANG RICHARD L (US) 2026-02-12 US claimed
EP-4662203-A1 BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS Translatum Medicus Inc. (CA) 2025-12-17 EP claimed
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2025-08-28 US claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
US-12257371-B2 SiOx barrier for pharmaceutical package and coating process SIO2 MEDICAL PRODUCTS, LLC (US) 2025-03-25 US claimed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
US-20240382597-A1 FORMULATIONS OF ANTI-INFLAMMATORY AGENTS COMPRISING MSM WITH ENHANCED SOLUBILITY IN WATER LIVIONEX INC (US) 2024-11-21 US claimed
WO-2024165925-A1 BINDARIT CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES OR DISORDERS Translatum Medicus Inc. (CA) 2024-08-15 WO claimed
CN-117979991-A Methods for treating, ameliorating or preventing infections using drug and vaccination combination therapy 拓比利亚欧斯特有限公司(ACN 652 771 670) 2024-05-03 CN claimed
WO-2004096217-A1 USE OF N-TYPE CALCIUM CHANNEL INHIBITORS IN TREATING DEMYELINATING DISEASES EISAI LONDON RESEARCH LABORATORIES LIMITED (GB) 2004-11-11 WO claimed
US-20040132804-A1 Cannabinoid receptor ligands SCHERING CORPORATION 2004-07-08 US claimed
US-20040057936-A1 Method to treat collagenous connective tissue for implant remodeled by host cells into living tissue CHEUNG DAVID T (US) 2004-03-25 US claimed
US-20040044051-A1 Cannabinoid receptor agonists SCHERING CORPORATION 2004-03-04 US claimed
WO-2004000807-A1 CANNABINOID RECEPTOR AGONISTS SCHERING CORPORATION (US) 2003-12-31 WO claimed
EP-0847277-A1 TREATMENT OF OCULAR INFLAMMATORY CONDITIONS WITH INTERLEUKIN-10 SCHERING CORPORATION (US) 1998-06-17 EP claimed
WO-1997005895-A1 TREATMENT OF OCULAR INFLAMMATORY CONDITIONS WITH INTERLEUKIN-10 SCHERING CORPORATION (US) 1997-02-20 WO claimed
EP-0664695-A1 METHOD AND COMPOSITION FOR TREATING MUCO-EPIDERMAL AND EPIDERMAL PAIN, INFLAMMATION AND INFECTION Embro, William J. (US) 1995-08-02 EP claimed
WO-1995004520-A1 METHOD AND COMPOSITION FOR TREATING MUCO-EPIDERMAL AND EPIDERMAL PAIN, INFLAMMATION AND INFECTION EMBRO WILLIAM J (US) 1995-02-16 WO claimed
CN-1084064-A Contain hyaluronic preparation NORPHARMCO INC (CA) 1994-03-23 CN claimed